InsidersTradesSigma
Track the SELLAS Life Sciences Group, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, SELLAS Life Sciences Group, Inc. has recorded 60 insider filings. Market capitalisation: €2.6bn. The latest transaction was filed on 9 January 2026 (Attribution). Among the most active insiders: Burns John Thomas. All data is accessible without an account.
60
Insider Decl.
n/a
Thresholds
€161,416
4 ops.
Buy Volume
€41,866
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SELLAS Life Sciences Group, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$27.50.
38Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 January 2026
Declarations60 total
50,000 shares0Common StockSEC:0001104659-26-002515:0
50,000 shares0Common StockSEC:0001104659-26-002511:0
50,000 shares0Common StockSEC:0001104659-26-002509:0
300,000 shares0Common StockSEC:0001104659-26-002506:0
300,000 shares0Common StockSEC:0001104659-26-002502:0
50,000 shares0Common StockSEC:0001104659-26-002499:0
50,000 shares0Common StockSEC:0001104659-26-002491:0
63,800 shares@ US$1.5090.3% of flowCommon StockSEC:0001104659-25-118882:0
58,592 shares@ US$1.5083.7% of flowCommon StockSEC:0001104659-25-118878:0
187,066 shares@ US$1.5077.4% of flowCommon StockSEC:0001104659-25-118872:0
63,400 shares@ US$1.5973.2% of flowCommon StockSEC:0001104659-25-114806:0
Canonical exit: 17 Feb 2026 (T+90)
10,000 shares@ US$1.48100.0% of flowCommon StockSEC:0001104659-25-059166:0
Canonical exit: 10 Sept 2025 (T+90)
20,000 shares@ US$1.69100.0% of flowCommon StockSEC:0001104659-25-055495:0
Canonical exit: 28 Aug 2025 (T+90)
20,000 shares@ US$1.80100.0% of flowCommon StockSEC:0001104659-25-051980:0
Canonical exit: 20 Aug 2025 (T+90)
257,000 shares0Common StockSEC:0001104659-25-003501:0
12,500 shares0Common StockSEC:0001104659-25-003499:0
12,500 shares0Common StockSEC:0001104659-25-003497:0
12,500 shares0Common StockSEC:0001104659-25-003498:0
113,000 shares0Common StockSEC:0001104659-25-003502:0
113,000 shares0Common StockSEC:0001104659-25-003494:0
12,500 shares0Common StockSEC:0001104659-25-003496:0
12,500 shares0Common StockSEC:0001104659-25-003495:0
8,256 shares@ US$1.13100.0% of flowCommon StockSEC:0001104659-24-125944:0
7,165 shares@ US$1.1348.0% of flowCommon StockSEC:0001104659-24-125942:0
28,289 shares@ US$1.1337.0% of flowCommon StockSEC:0001104659-24-125943:0
25 of 60 declarations
关于 SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) 是一家在美国上市的临床阶段生物制药公司，总部位于美国纽约。SELLAS 成立于 2012 年，其核心是专注于肿瘤学的研发模式，而非商业制药平台，这意味着其估值主要受临床里程碑、监管反馈和融资事件驱动。对于投资者而言，这使得该公司处于小型生物技术公司的高风险/高回报细分市场，其股价表现可能对试验数据和融资活动反应剧烈。（[ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/company/default.aspx?utm_source=openai)） 该公司的战略围绕两个主要资产：galinpepimut-S (GPS) 和 SLS009。GPS 是一种从 Memorial Sloan Kettering Cancer Center 获得许可的癌症免疫疗法，主要通过关键的 3 期 REGAL 试验在急性髓系白血病 (AML) 中进行开发。SLS009 是一种靶向肿瘤学候选药物，也在 AML 中取得进展，SELLAS 报告称在 2025 年复发/难治性 AML 中获得了积极的 2 期数据，并正在推动该项目进行一线研究。这些项目共同使 SELLAS 涉足血液肿瘤学领域，这是一个持续存在未满足医疗需求且对差异化机制有强烈兴趣的领域。（[ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/?utm_source=openai)） 在竞争方面，SELLAS 仍然是一家处于开发阶段的生物技术公司，多元化程度有限。其上行空间取决于其主要项目能否提供具有临床意义的疗效，并最终支持监管批准，如果成功，则进行商业化或合作。该公司的竞争优势来自于其方法的创新性以及两个核心资产都已处于相对高级阶段的事实，这可以创造近期催化剂。同时，该股票保留了经典的生物技术风险：二元试验结果、稀释风险以及临床时间表可能延迟的可能性。最近的文件和公司更新也显示，公司持续关注资产负债表管理，包括在 2025 年和 2026 年通过行使认股权证改善了现金资源。（[ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update/default.aspx?utm_source=openai)） 从地理上看，SELLAS 在美国纽约运营，并依靠研究和临床合作伙伴网络来开展其开发项目。最近的主要新闻集中在 GPS 的 REGAL 3 期试验进展、最终分析所需的事件数量、SLS009 扩展到新诊断的 AML 以及该公司的最新季度和全年更新。对于法国、比利时和瑞士的法语投资者而言，SELLAS 最好被视为一家在美国纳斯达克上市的肿瘤生物技术公司，拥有集中的产品线、重要的临床催化剂以及可能对数据发布和融资条件高度敏感的估值状况。（[ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspx?utm_source=openai)）
